Chronic obstructive pulmonary disease and its treatment in the Russian Federation: Results of a cross-sectional assessment from the CORSAIR observational study

V. V. Arkhipov; S. N. Avdeev; V. I. Trofimov; G. L. Osipova; E. M. Vishneva; О. A. Shangina; N. A. Kirillova; Т. A. Lagutina; E. I. Van’kova; I. A. Shipilova; J. M. Ilkovich; О. Y. Ananeva

doi:10.18093/0869-0189-2024-34-5-676-687

Chronic obstructive pulmonary disease and its treatment in the Russian Federation: Results of a cross-sectional assessment from the CORSAIR observational study

https://doi.org/10.18093/0869-0189-2024-34-5-676-687

Full Text:

PDF (Rus)

Generate QR code

Abstract

Abstract Up-to-date data on patients with chronic obstructive pulmonary disease (COPD) in the Russian Federation are necessary to improve medical care effectiveness.

This article presents the results of the retrospective part and the cross-sectional assessment of the CORSAIR study, which aimed to assess the distribution of COPD patients in the Russian population by symptom severity and exacerbation risk as per GOLD (2020) classification groups A, B, C, D.

Methods. The observational multicenter study CORSAIR included a cross-sectional assessment with data collection during the previous 12 months (retrospective part) and subsequent follow-up for 12 months (prospective part). Data from 704 patients obtained at 18 study sites from August 2021 to November 2022 are presented. At the first visit, the physician recorded medical history, clinical data on the disease course, and COPD therapy, assessed compliance of treatment with national guidelines, and determined whether treatment change was needed considering the predominant treatable trait (dyspnea or exacerbation).

Results. Upon inclusion, most patients had severe COPD symptoms (mMRC score ≥ 2; САТ score ≥ 10) and severe and very severe airflow obstruction (GOLD III and GOLD IV; FEV1 < 50% оf predicted). More than half of the patients had at least one moderate or severe COPD exacerbation within the previous 12 months. As per the GOLD (2020) classification, 57.2% of patients belonged to Group B (severe symptoms and low risk of exacerbations) and 30.3% to Group D (severe symptoms and high risk of exacerbations). 58.8% of patients received treatment that was not compliant with national clinical guidelines in force at the study initiation. 31.7% of patients had not COPD control. Blood eosinophil count was above 300 cells/μL in 15.1% of patients.

Conclusion. In most cases, patients had severe COPD symptoms with frequent exacerbations, and the prescribed treatment did not comply with national clinical guidelines. These data will be analyzed alongside the prospective study results.

Keywords

chronic obstructive pulmonary disease, COPD, Russian population, observational study, treatable traits, eosinophilia, exacerbations

About the Authors

V. V. Arkhipov

Federal State Budgetary Educational Institution of Additional Professional Education “Russian Medical Academy of Continuous Professional Education”, Ministry of Health of Russia
Russian Federation

Vladimir V. Arkhipov - Doctor of Medicine, Professor, Department of Clinical Pharmacology and Therapy.

Ul. Barrikadnaya 2/1, Moscow, 123995; tel.: (499) 252-21-04

Competing Interests:

received fees for scientific consulting services from the GlaxoSmithKline group of companies, fees for lectures from AstraZeneca, Boehringer Ingelheim, Novartis, Roche, Zambon Pharma, and Chiesi Farmaceutici

S. N. Avdeev

Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University); Federal State Budgetary Institution “Pulmonology Scientific Research Institute” under Federal Medical and Biological Agency of Russian Federation
Russian Federation

Sergey N. Avdeev - Doctor of Medicine, Professor, Academician of Russian Academy of Sciences, Head of the Department of Pulmonology, N.V.Sklifosovsky Institute of Clinical Medicine, Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First MSMU of the Ministry of Health of the Russian Federation (Sechenov University), Leading Researcher, Pulmonology Scientific Research Institute.

Ul. Trubetskaya 8, build. 2, Moscow, 119991; Orekhovyy bul’var 28, Moscow, 115682. tel.: (495) 708-35-76

Competing Interests:

received fees for scientific consulting services from the GlaxoSmithKline group of companies and fees for lectures from AstraZeneca

V. I. Trofimov

Federal State Budgetary Educational Institution of Higher Education “Academician I.P. Pavlov First St. Petersburg State Medical University” of the Ministry of Healthcare of Russian Federation
Russian Federation

Vasily I. Trofimov - Doctor of Medicine, Professor, Head of Department of Hospital Therapy.

Ul. L`va Tolstogo 6 – 8, Saint-Petersburg, 197022; tel.: (812) 338-71-53

Competing Interests: